Download App

Log in to access Online Inquiry
Company Overview More
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
CEO: Mullen, James C.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

EDIT Editas Medicine
10.890-0.130-1.18%
Post Mkt Price
10.600-0.29-2.66%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-21.9% 488.36M 24.31% 499.85M 21.13% 619.92M 12.63% 557.84M
-Cash and cash equivalents
-40.58% 210.88M 45.7% 203.52M -- -- -7.04% 259.88M
-Short-term investments
2.61% 277.48M 12.92% 296.33M -- -- 38.12% 297.96M
Receivables
104.02% 1.37M -95.59% 267K -- -- -76.21% 251K
-Accounts receivable
104.02% 1.37M -95.59% 267K -- -- -76.21% 251K
Prepaid assets
15.64% 7.3M -34.14% 7.2M -- -- -9.09% 9.52M
Total current assets
-21.4% 497.03M 21.05% 507.31M -- -- 11.99% 567.61M
Non current assets
Net PPE
-6.19% 40.72M 10.58% 43.29M -- -- 7.33% 43.43M
-Gross PPE
4.32% 57.78M 17.03% 58.8M -- -- 14.07% 57.48M
-Accumulated depreciation
-42.34% -17.06M -39.77% -15.51M -- -- -41.58% -14.04M
Investments and advances
-20.27% 78.05M 9.49% 120.07M -- -- 115.71% 99.2M
Other non current assets
9.39% 7.32M 44.82% 6.81M -- -- 74.9% 6.78M
Total non current assets
-14.8% 126.08M 10.85% 170.17M -- -- 65.41% 149.41M
Total assets
-20.14% 623.11M 18.32% 677.48M 18.32% 677.48M 20.07% 717.02M
Liabilities
Current liabilities
Payables
-47.33% 4.69M -21.19% 5.05M -- -- -34.04% 3.4M
-accounts payable
-47.33% 4.69M -21.19% 5.05M -- -- -34.04% 3.4M
Current accrued expenses
-4.55% 10.21M -46.41% 10.03M -- -- -63.9% 4.94M
Current debt and capital lease obligation
40.5% 10.21M 51.36% 10.31M -- -- 61.83% 10.26M
-Current capital lease obligation
40.5% 10.21M 51.36% 10.31M -- -- 61.83% 10.26M
Current deferred liabilities
-82.21% 5.82M -45.89% 11.33M -- -- 14.05% 22.67M
Current liabilities
-42.97% 36.5M -19.45% 46.88M -- -- -7.13% 50.91M
Non current liabilities
Long term debt and capital lease obligation
-40.07% 12.96M -16.84% 16.07M -- -- -9.51% 18.43M
-Long term capital lease obligation
-40.07% 12.96M -16.84% 16.07M -- -- -9.51% 18.43M
Non current deferred liabilities
7.45% 60.89M -17.7% 60.89M -- -- -24.66% 60.89M
Total non current liabilities
-5.68% 73.85M -36.3% 76.96M -- -- -21.61% 79.32M
Total liabilities
-22.45% 110.35M -30.82% 123.84M -30.82% 123.84M -16.53% 130.23M
Shareholders'equity
Share capital
0% 7K 16.67% 7K -- -- 16.67% 7K
-common stock
0% 7K 16.67% 7K -- -- 16.67% 7K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
-25.8% -908.21M -28.94% -857.7M -- -- -35.43% -816.26M
Paid-in capital
4.67% 1.42B 33.34% 1.41B -- -- 34.41% 1.4B
Gains losses not affecting retained earnings
-3336.99% -2.51M -971.74% -493K -- -- -33.33% -64K
Total stockholders'equity
-19.63% 512.76M 40.67% 553.64M 40.67% 553.64M 33.01% 586.79M
Total equity
-19.63% 512.76M 40.67% 553.64M 40.67% 553.64M 33.01% 586.79M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%